Identifying Peripheral Biomarkers and Evaluating Treatment Outcomes for Neuromyelitis Optica Spectrum Disorder

Recent studies have identified promising peripheral inflammatory biomarkers that can predict NMOSD disease relapse, and newer treatments like satralizumab and eculizumab demonstrate superior efficacy and safety compared to traditional therapies.